But_home
But_blogshome
But_forum
Icon_rss_infobarSubscribe to receive updates
on new articles and posts from this blog.
 
Latest 5 articles from heartwire

Dabigatran: Crossing a remarkable threshold

Posted Oct 14, 2009 at 11:00 AM, EDT by Eric Topol

The exciting results of the RE-LY trial appear to mark the beginning of a new era in anticoagulation for atrial fibrillation. Will dabigatran be the drug to replace warfarin, at last? How do you think these findings will improve patient care? 

Disclosure: I have no relationship with the dabigatran's manufacturer (Boehringer Ingleheim) or any other forthcoming oral anticoagulant program in clinical development (DTI, Factor Xa, etc).

See:

RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib

Best of Barcelona: PLATO and RE-LY

The Bob Harrington Show Episode #13: RE-LY and PLATO: Direct from ESC Congress 2009 with Ph Gabriel Steg

RE-LY: An obituary for Warfarin?

 

No commentsAucun commentaire | Post a comment | Permalink
Also from theheart.org
Topol and Teirstein: The Click and Rub Show
This week in cardiology from heartwire
The Bob Harrington Show
Private practice with Dr Seth Bilazarian
Fellows' corner
Heartfelt with Dr Melissa Walton-Shirley
Clotblog with Dr Samuel Goldhaber
Blogs I read


Who's talking
Photo
Eric J Topol MD
Director, Scripps Translational Science Institute
The Gary and Mary West Chair of Innovative Medicine
Chief Academic Officer, Scripps Health
La Jolla, CA